FDA Grants Jemperli Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer

The FDA granted Jemperli (dostarlimab-gxly) a breakthrough therapy designation for locally advanced dMMR/MSI-H rectal cancer, marking its second designation for this population. Jemperli showed a 100% clinical complete response rate in a phase 2 trial, supporting its potential to improve treatment for patients with this condition.


Related News

FDA Grants Jemperli Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer

The FDA granted Jemperli (dostarlimab-gxly) a breakthrough therapy designation for locally advanced dMMR/MSI-H rectal cancer, marking its second designation for this population. Jemperli showed a 100% clinical complete response rate in a phase 2 trial, supporting its potential to improve treatment for patients with this condition.

© Copyright 2024. All Rights Reserved by MedPath